OverviewSuggest Edit

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

TypePublic
Founded2002
HQPlano, US
Websitereatapharma.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2019)220(+79%)
Revenue (FY, 2019)$26.5 M(-44%)
Share Price (Nov 2020)$174.4 (-2%)
Cybersecurity ratingBMore

Key People/Management at Reata Pharmaceuticals

Warren Huff

Warren Huff

Founding Chief Executive Officer and President, Director
Dawn C. Bir

Dawn C. Bir

Chief Commercial Officer and Executive Vice President
Colin Meyer

Colin Meyer

Chief Research & Development Officer and Executive Vice President
Manmeet S. Soni

Manmeet S. Soni

Chief Operating Officer & Chief Financial Officer and Executive Vice President
Michael D. Wortley

Michael D. Wortley

Chief Legal Officer and Executive Vice President
Joel Proksch

Joel Proksch

Senior Vice President, Chief Development Operations Officer
Show more

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has offices in Plano and Irving
Plano, US (HQ)
5320 Legacy Dr
Irving, US
2801 Gateway Dr #150
Plano, US
5340 Legacy Dr
Show all (3)

Reata Pharmaceuticals Financials and Metrics

Reata Pharmaceuticals Revenue

Reata Pharmaceuticals's revenue was reported to be $26.52 m in FY, 2019
USD

Revenue (Q2, 2020)

3.1m

Net income (Q2, 2020)

(67.6m)

Market capitalization (12-Nov-2020)

5.9b

Closing stock price (12-Nov-2020)

174.4

Cash (30-Jun-2020)

610.4m
Reata Pharmaceuticals's current market capitalization is $5.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

50.3m49.9m48.1m26.5m

Revenue growth, %

(1%)(4%)

General and administrative expense

13.7m16.6m23.3m32.7m58.3m

R&D expense

35.1m39.5m71.3m97.3m128.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

32.4m7.6m5.2m7.8m8.2m1.4m3.1m

General and administrative expense

4.5m4.0m5.2m6.0m6.2m6.6m10.7m7.5m10.0m11.7m14.3m20.8m16.6m

R&D expense

9.1m9.3m14.6m17.9m18.3m21.4m23.4m27.1m26.1m29.6m32.3m47.7m36.8m

Operating expense total

13.8m13.5m19.9m24.0m24.6m28.1m34.2m34.7m36.3m41.3m46.6m68.4m53.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

42.0m84.7m129.8m337.8m664.3m

Prepaid Expenses

3.3m4.5m5.0m

Inventories

2.6m

Current Assets

77.3m87.3m133.1m342.3m669.3m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

92.4m95.7m82.7m65.2m154.6m105.9m138.7m375.2m313.1m280.4m240.1m624.5m610.4m

Prepaid Expenses

2.5m3.3m4.6m4.4m6.8m6.4m5.2m7.8m

Current Assets

112.9m99.9m85.7m68.9m157.8m134.7m172.4m379.8m317.5m287.2m246.5m651.9m640.5m

PP&E

942.0k899.0k703.0k671.0k774.0k829.0k810.0k795.0k2.7m2.8m2.9m3.9m4.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.4m)(6.2m)(47.7m)(80.5m)(290.2m)

Depreciation and Amortization

1.8m682.0k437.0k431.0k932.0k

Inventories

(1.2m)

Accounts Payable

299.0k(1.8m)2.0m(2.1m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.2m)(2.1m)(7.1m)(18.7m)(31.0m)4.1m(24.1m)(55.0m)(29.2m)(63.5m)(103.2m)(48.9m)(116.5m)

Depreciation and Amortization

367.0k537.0k130.0k282.0k414.0k101.0k206.0k311.0k170.0k401.0k659.0k278.0k562.0k

Accounts Payable

(2.2m)(2.2m)(3.3m)(1.2m)(1.4m)(1.1m)46.0k2.9m(522.0k)312.0k(440.0k)10.7m9.4m

Cash From Operating Activities

(11.8m)(8.1m)(22.1m)(39.5m)(58.5m)(24.0m)(49.4m)(46.3m)(28.7m)(61.4m)(101.8m)(41.2m)(237.1m)
USDFY, 2015

Financial Leverage

-0.3 x
Show all financial metrics

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Patents Pending

280

Phase I Trials Products

2

Phase III Trials Products

1
Show all operating metrics

Reata Pharmaceuticals Revenue Breakdown

Embed Graph

Reata Pharmaceuticals revenue breakdown by business segment: 98.0% from License and Milestone and 2.0% from Other

Reata Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Reata Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Reata Pharmaceuticals Online and Social Media Presence

Embed Graph

Reata Pharmaceuticals News and Updates

Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME

ROSEN, A TOP RANKED LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class Period”), of the important December 14, 2020 lead pla…

ROSEN, RECOGNIZED INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – RETA

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class P…

RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA) and certain of its officers, on behalf of sharehold…

Pomerantz Law Firm Announces the Filing of a Class Action against Reata Pharmaceuticals, Inc. and Certain Officers - RETA

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and certain of its officers. The class action, filed in United States District Court for the Eastern...

Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 2020 Reimagined

PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease, as an e-poster to be presented at the American Society of Neph…
Show more

Reata Pharmaceuticals Blogs

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020 Content Import Mon, 11/02/2020 - 17:30 Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Developmen…

Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

PLANO, Texas , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that results from the pivotal part 2 portion of the MOXIe trial evaluating the efficacy and safety of

Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors

PLANO, Texas , July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards , M.D. to its Board of Directors, effective August 3, 2020 .  Since 2003,

Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs

Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs Content Import Mon, 05/11/2020 - 16:02 Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs …

Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020

Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020 Content Import Mon, 05/04/2020 - 16:36 Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Developm…

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations Content Import Mon, 03/30/2020 - 16:06 Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations …
Show more

Reata Pharmaceuticals Frequently Asked Questions

  • When was Reata Pharmaceuticals founded?

    Reata Pharmaceuticals was founded in 2002.

  • Who are Reata Pharmaceuticals key executives?

    Reata Pharmaceuticals's key executives are Warren Huff, Dawn C. Bir and Colin Meyer.

  • How many employees does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 220 employees.

  • What is Reata Pharmaceuticals revenue?

    Latest Reata Pharmaceuticals annual revenue is $26.5 m.

  • What is Reata Pharmaceuticals revenue per employee?

    Latest Reata Pharmaceuticals revenue per employee is $120.5 k.

  • Who are Reata Pharmaceuticals competitors?

    Competitors of Reata Pharmaceuticals include Inovio Pharmaceuticals, MyoKardia and Athersys.

  • Where is Reata Pharmaceuticals headquarters?

    Reata Pharmaceuticals headquarters is located at 5320 Legacy Dr, Plano.

  • Where are Reata Pharmaceuticals offices?

    Reata Pharmaceuticals has offices in Plano and Irving.

  • How many offices does Reata Pharmaceuticals have?

    Reata Pharmaceuticals has 3 offices.